Genesystem Co. Ltd.
Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterina… Read more
Genesystem Co. Ltd. (363250) - Net Assets
Latest net assets as of September 2025: ₩15.51 Billion KRW
Based on the latest financial reports, Genesystem Co. Ltd. (363250) has net assets worth ₩15.51 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩23.55 Billion) and total liabilities (₩8.04 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩15.51 Billion |
| % of Total Assets | 65.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | 56.49% |
| 10-Year Change | N/A |
| Growth Volatility | 122.14 |
Genesystem Co. Ltd. - Net Assets Trend (2018–2024)
This chart illustrates how Genesystem Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genesystem Co. Ltd. (2018–2024)
The table below shows the annual net assets of Genesystem Co. Ltd. from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩19.27 Billion | -29.81% |
| 2023-12-31 | ₩27.46 Billion | -21.80% |
| 2022-12-31 | ₩35.11 Billion | -20.36% |
| 2021-12-31 | ₩44.09 Billion | +257.96% |
| 2020-12-31 | ₩12.32 Billion | +197.01% |
| 2019-12-31 | ₩-12.70 Billion | -43.52% |
| 2018-12-31 | ₩-8.85 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genesystem Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1242248305000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩3.17 Billion | 16.44% |
| Common Stock | ₩3.52 Billion | 18.25% |
| Other Components | ₩12.59 Billion | 65.31% |
| Total Equity | ₩19.27 Billion | 100.00% |
Genesystem Co. Ltd. Competitors by Market Cap
The table below lists competitors of Genesystem Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
University Bancorp Inc
OTCQB:UNIB
|
$21.22 Million |
|
Duluth Holdings Inc
NASDAQ:DLTH
|
$21.22 Million |
|
Eslite Spectrum
TWO:2926
|
$21.23 Million |
|
Alony Hetz Properties and Investments Ltd
TA:ALHE
|
$21.23 Million |
|
Zero to Seven Inc
KQ:159580
|
$21.22 Million |
|
Company K Partners Limited
KQ:307930
|
$21.22 Million |
|
Lycos Energy Inc.
F:G4P0
|
$21.21 Million |
|
Safe Bulkers Inc
NYSE:SB
|
$21.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genesystem Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 27,456,223,870 to 19,272,671,430, a change of -8,183,552,440 (-29.8%).
- Net loss of 8,915,298,500 reduced equity.
- Share repurchases of 1,306,020,010 reduced equity.
- New share issuances of 211,570,560 increased equity.
- Other factors increased equity by 1,826,195,510.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-8.92 Billion | -46.26% |
| Share Repurchases | ₩1.31 Billion | -6.78% |
| Share Issuances | ₩211.57 Million | +1.1% |
| Other Changes | ₩1.83 Billion | +9.48% |
| Total Change | ₩- | -29.81% |
Book Value vs Market Value Analysis
This analysis compares Genesystem Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.00x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ₩-1298.76 | ₩5660.00 | x |
| 2019-12-31 | ₩-1863.98 | ₩5660.00 | x |
| 2020-12-31 | ₩1808.18 | ₩5660.00 | x |
| 2021-12-31 | ₩6408.50 | ₩5660.00 | x |
| 2022-12-31 | ₩5066.46 | ₩5660.00 | x |
| 2023-12-31 | ₩3930.80 | ₩5660.00 | x |
| 2024-12-31 | ₩2829.86 | ₩5660.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genesystem Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -738.17%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.55x
- Recent ROE (-46.26%) is below the historical average (-15.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -496.25% | 0.12x | 0.00x | ₩-1.59 Billion |
| 2019 | 0.00% | -356.08% | 0.56x | 0.00x | ₩-2.77 Billion |
| 2020 | -18.06% | -16.77% | 0.70x | 1.54x | ₩-3.46 Billion |
| 2021 | 8.06% | 26.83% | 0.26x | 1.15x | ₩-857.08 Million |
| 2022 | -25.62% | -246.26% | 0.09x | 1.17x | ₩-12.51 Billion |
| 2023 | -28.83% | -882.41% | 0.02x | 1.42x | ₩-10.66 Billion |
| 2024 | -46.26% | -738.17% | 0.04x | 1.55x | ₩-10.84 Billion |
Industry Comparison
This section compares Genesystem Co. Ltd.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $80,735,275,073
- Average return on equity (ROE) among peers: -13.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genesystem Co. Ltd. (363250) | ₩15.51 Billion | 0.00% | 0.52x | $21.22 Million |
| NSN Co. Ltd (031860) | $102.59 Billion | 0.00% | 0.91x | $4.54 Million |
| JOONGANG DNM Co.Ltd (051980) | $24.46 Billion | -32.51% | 0.43x | $77.93 Million |
| GeneMatrix Inc (109820) | $32.32 Billion | -3.06% | 0.22x | $21.53 Million |
| Genoray Co. Ltd (122310) | $11.35 Billion | 17.59% | 1.51x | $24.43 Million |
| Green Cross Lab Cell Corporation (144510) | $457.79 Billion | -16.14% | 0.26x | $147.96 Million |
| Optipharm.CO.LTD (153710) | $25.14 Billion | -9.69% | 0.56x | $30.10 Million |
| Cytogen Inc (217330) | $48.58 Billion | -35.23% | 0.49x | $27.02 Million |
| U2Bio Co., Ltd. (221800) | $33.84 Billion | 38.88% | 0.51x | $84.13 Million |
| Gencurix Inc (229000) | $8.20 Billion | -110.48% | 0.13x | $21.11 Million |
| P&K Skin Research Center Co. Ltd (347740) | $63.07 Billion | 11.56% | 0.06x | $15.93 Million |